{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:23:13Z","timestamp":1792293793770,"version":"4.4.0"},"reference-count":187,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T00:00:00Z","timestamp":1552435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1108859"],"award-info":[{"award-number":["APP1108859"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Since their discovery in the early 20th century, antibiotics have been used as the primary weapon against bacterial infections. Due to their prophylactic effect, they are also used as part of the cocktail of drugs given to treat complex diseases such as cancer or during surgery, in order to prevent infection. This has resulted in a decrease of mortality from infectious diseases and an increase in life expectancy in the last 100 years. However, as a consequence of administering antibiotics broadly to the population and sometimes misusing them, antibiotic-resistant bacteria have appeared. The emergence of resistant strains is a global health threat to humanity. Highly-resistant bacteria like Staphylococcus aureus (methicillin-resistant) or Enterococcus faecium (vancomycin-resistant) have led to complications in intensive care units, increasing medical costs and putting patient lives at risk. The appearance of these resistant strains together with the difficulty in finding new antimicrobials has alarmed the scientific community. Most of the strategies currently employed to develop new antibiotics point towards novel approaches for drug design based on prodrugs or rational design of new molecules. However, targeting crucial bacterial processes by these means will keep creating evolutionary pressure towards drug resistance. In this review, we discuss antibiotic resistance and new options for antibiotic discovery, focusing in particular on new alternatives aiming to disarm the bacteria or empower the host to avoid disease onset.<\/jats:p>","DOI":"10.3390\/ijms20061255","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T04:15:29Z","timestamp":1552536929000},"page":"1255","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["Thinking Outside the Bug: Molecular Targets and Strategies to Overcome Antibiotic Resistance"],"prefix":"10.3390","volume":"20","author":[{"given":"Ana","family":"Monserrat-Martinez","sequence":"first","affiliation":[{"name":"European Molecular Biology Laboratory Australia (EMBL Australia) Node in Single Molecule Science, Sydney, NSW 2031, Australia"},{"name":"School of Medical Sciences, The University of New South Wales, Sydney, NSW 2031, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Gambin","sequence":"additional","affiliation":[{"name":"European Molecular Biology Laboratory Australia (EMBL Australia) Node in Single Molecule Science, Sydney, NSW 2031, Australia"},{"name":"School of Medical Sciences, The University of New South Wales, Sydney, NSW 2031, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Sierecki","sequence":"additional","affiliation":[{"name":"European Molecular Biology Laboratory Australia (EMBL Australia) Node in Single Molecule Science, Sydney, NSW 2031, Australia"},{"name":"School of Medical Sciences, The University of New South Wales, Sydney, NSW 2031, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,3,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.drup.2011.02.001","article-title":"Fighting bacterial infections\u2014Future treatment options","volume":"14","author":"Fernebro","year":"2011","journal-title":"Drug Resist. Updat."},{"key":"ref_2","first-page":"226","article-title":"On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenz\u00e6","volume":"10","author":"Fleming","year":"1929","journal-title":"Br. J. Exp. Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3181\/00379727-51-13986","article-title":"Resistance of Staphylococcus aureus to the action of penicillin","volume":"51","author":"Rammelkamp","year":"1942","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.1073\/pnas.122108599","article-title":"The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA)","volume":"99","author":"Enright","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4103\/0974-777X.59251","article-title":"Revisiting methicillin-resistant Staphylococcus aureus infections","volume":"2","author":"Waness","year":"2010","journal-title":"J. Glob. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Fischer, J., and Ganellin, C.R. (2006). Analogue-Based Drug Discovery, Wiley-VCH. [1st ed.].","DOI":"10.1002\/3527608001"},{"key":"ref_7","unstructured":"Lemke, T. (2008). Foye\u2019s Principles of Medicinal Chemistry, Lippincott Williams & Wilkins. [6th ed.]."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S1045-1870(99)80005-3","article-title":"New cephalosporins","volume":"10","author":"Singh","year":"1999","journal-title":"Semin. Pediatr. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/j.1875-9114.1998.tb03925.x","article-title":"Levofloxacin, a second-generation fluoroquinolone","volume":"5","author":"North","year":"1998","journal-title":"Pharmacotherapy"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1086\/491709","article-title":"Vancomycin: A history","volume":"42","author":"Levine","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/472032a","article-title":"Fix the antibiotics pipeline","volume":"472","author":"Cooper","year":"2011","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd2201","article-title":"Drugs for bad bugs: Confronting the challenges of antibacterial discovery","volume":"6","author":"Payne","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/1751-7915.12123","article-title":"Discovering new bioactive molecules from microbial sources","volume":"7","author":"Monciardini","year":"2014","journal-title":"Microb. Biotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00253-011-3587-6","article-title":"Penicillin: The medicine with the greatest impact on therapeutic outcomes","volume":"92","author":"Kardos","year":"2011","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Munita, J.M., and Arias, C.A. (2016). Mechanisms of Antibiotic Resistance. Microbiol. Spectr., 4.","DOI":"10.1128\/microbiolspec.VMBF-0016-2015"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nrmicro1994","article-title":"The porin and the permeating antibiotic: A selective diffusion barrier in gram-negative bacteria","volume":"6","author":"Pages","year":"2008","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/jac\/dki171","article-title":"Efflux-mediated antimicrobial resistance","volume":"56","author":"Poole","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd2202","article-title":"Multi-targeting by monotherapeutic antibacterials","volume":"6","author":"Silver","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0163-7258(82)90053-5","article-title":"Vancomycin and related antibiotics","volume":"16","author":"Perkins","year":"1982","journal-title":"Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20150024","DOI":"10.1098\/rstb.2015.0024","article-title":"Bacterial cell wall composition and the influence of antibiotics by cell-wall and whole-cell NMR","volume":"370","author":"Romaniuk","year":"2015","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"ref_21","unstructured":"Baron, S. (1996). Chapter 11: Antimicrobial Chemotherapy. Medical Microbiology, University of Texas Medical Branch at Galveston. [4th ed.]."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJM200003093421007","article-title":"Vancomycin-resistant Enterococcal infections","volume":"342","author":"Murray","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1574-6968.1992.tb05089.x","article-title":"Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus","volume":"93","author":"Noble","year":"1992","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1128\/AAC.44.11.3224-3228.2000","article-title":"Genetic characterization of vanG, a novel vancomycin resistance locus of Enterococcus faecalis","volume":"44","author":"McKessar","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1074-5521(96)90079-4","article-title":"Bacterial resistance to vancomycin: Five genes and one missing hydrogen bond tell the story","volume":"3","author":"Walsh","year":"1996","journal-title":"Chem. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"11952","DOI":"10.1021\/acs.chemrev.6b00820","article-title":"Total syntheses of vancomycin-related glycopeptide antibiotics and key analogues","volume":"117","author":"Okano","year":"2017","journal-title":"Chem. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"13946","DOI":"10.1021\/ja207142h","article-title":"A Redesigned vancomycin engineered for dual d-Ala-d-Ala and d-Ala-d-Lac binding exhibits potent antimicrobial activity against vancomycin-resistant bacteria","volume":"133","author":"Xie","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1039\/b416648p","article-title":"Natural products to drugs: Daptomycin and related lipopeptide antibiotics","volume":"22","author":"Baltz","year":"2005","journal-title":"Nat. Prod. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1021\/jm800038g","article-title":"Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections","volume":"51","author":"Brickner","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_30","first-page":"114","article-title":"Peripheral modifications of vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics","volume":"26","author":"Okano","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","first-page":"231","article-title":"Chemistry of the ansamycin antibiotics","volume":"33","author":"Rinehart","year":"1976","journal-title":"Fortschr. Chem. Org. Naturst."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BFb0048448","article-title":"Ansamycins. Chemistry, biosynthesis and biological activity","volume":"72","author":"Wehrli","year":"1977","journal-title":"Top. Curr. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1128\/am.9.4.325-334.1961","article-title":"Rifomycin. XIV. Production of rifomycin B","volume":"9","author":"Margalith","year":"1961","journal-title":"Appl. Microbiol."},{"key":"ref_34","first-page":"165","article-title":"Rifamycin. Activation of rifamycin B and rifamycin O. Production and properties of rifamycin S and rifamycin SV","volume":"16","author":"Sensi","year":"1961","journal-title":"Il Farmaco, Ed. Sci."},{"key":"ref_35","first-page":"21","article-title":"Production of rifamycins","volume":"6","author":"Sensi","year":"1967","journal-title":"Prog. Ind. Microbiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/207417a0","article-title":"Effect of rifamycin on protein synthesis","volume":"207","author":"Calvori","year":"1965","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0005-2787(67)90147-5","article-title":"The specific inhibition of the DNA-directed RNA synthesis by rifamycin","volume":"145","author":"Hartmann","year":"1967","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S407","DOI":"10.1093\/clinids\/5.Supplement_3.S407","article-title":"Rifampin: Mechanisms of action and resistance","volume":"5","author":"Wehrli","year":"1983","journal-title":"Rev. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1021\/cr030112j","article-title":"Rifamycin\u2014Mode of Action, Resistance, and Biosynthesis","volume":"105","author":"Floss","year":"2005","journal-title":"Chem. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1128\/am.20.5.810-814.1970","article-title":"Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis","volume":"20","author":"David","year":"1970","journal-title":"Appl. Microbiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1128\/AAC.46.2.267-274.2002","article-title":"Evolution of drug resistance in Mycobacterium tuberculosis: Clinical and molecular perspective","volume":"46","author":"Gillespie","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0092-8674(01)00286-0","article-title":"Structural mechanism for rifampicin inhibition of bacterial rna polymerase","volume":"104","author":"Campbell","year":"2001","journal-title":"Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/0-306-47384-4_15","article-title":"The use of esters as prodrugs for oral delivery of beta-lactam antibiotics","volume":"11","author":"Mizen","year":"1998","journal-title":"Pharm. Biotechnol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1021\/jm00298a005","article-title":"Acyloxymethyl esters of ampicillin","volume":"13","author":"Daehne","year":"1970","journal-title":"J. Med. Chem."},{"key":"ref_45","first-page":"442","article-title":"Clinical pharmacology of pivampicillin","volume":"10","author":"Foltz","year":"1970","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","first-page":"438","article-title":"Clinical pharmacology of pivampicillin as compared with ampicillin","volume":"10","author":"Jordan","year":"1970","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0007-0971(73)90057-0","article-title":"A comparison of pivampicillin and ampicillin in exacerbations of chronic bronchitis","volume":"67","author":"Pines","year":"1973","journal-title":"Br. J. Dis. Chest"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/CMR.00037-09","article-title":"Three decades of \u03b2-lactamase inhibitors","volume":"23","author":"Drawz","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.7164\/antibiotics.33.1183","article-title":"Mutual pro-drugs of \u03b2-lactam antibiotics and \u03b2-lactamase inhibitors","volume":"33","author":"Baltzer","year":"1980","journal-title":"J. Antibiot."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/j.1875-9114.1994.tb04167.x","article-title":"Ampicillin-sulbactam versus cefoxitin for prophylaxis in high-risk patients undergoing abdominal surgery","volume":"14","author":"Paladino","year":"1994","journal-title":"Pharmacotherapy"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/clinids\/24.1.57","article-title":"Cost-effectiveness of ampicillin\/sulbactam versus imipenem\/cilastatin in the treatment of limb-threatening foot infections in diabetic patients","volume":"24","author":"McKinnon","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/j.1875-9114.1998.tb03836.x","article-title":"Pharmacoeconomic analysis of ampicillin-sulbactam versus cefoxitin in the treatment of intraabdominal infections","volume":"18","author":"Messick","year":"1998","journal-title":"Pharmacotherapy"},{"key":"ref_53","unstructured":"Pfizer (2019, March 11). Unasyn (Ampicillin Sodium\/Sulbactam Sodium), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/050608s041s042lbl.pdf."},{"key":"ref_54","unstructured":"Clinical and Laboratory Standard Institute (2012). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement, Clinical and Laboratory Standard Institute. CLSI Document M100-S22."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2165\/00003495-200767130-00003","article-title":"Ampicillin\/sulbactam: Current status in severe bacterial infections","volume":"67","author":"Rafailidis","year":"2007","journal-title":"Drugs"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.shpsc.2005.07.003","article-title":"Integrating research and development: The emergence of rational drug design in the pharmaceutical industry","volume":"36","author":"Adam","year":"2005","journal-title":"Stud. Hist. Philos. Biol. Biomed. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/jac\/dkw450","article-title":"Linezolid: A promising option in the treatment of gram-positives","volume":"72","author":"Rahbar","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_58","unstructured":"European Medicines Agency (2012, March 15). CHP Assessment Report for Xarelto (EMA\/CHMP\/301607\/2011). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xarelto."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1086\/595686","article-title":"Complicated skin and skin-structure infections and catheter-related bloodstream infections: Noninferiority of linezolid in a phase 3 study","volume":"48","author":"Wilcox","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_60","unstructured":"(2018, December 01). Linezolid Side Effects in Detail. Available online: www.drugs.com."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Okafor, N. (2016). Chapter 28.2 Newer methods of drug discovery. Modern Industrial Microbiology and Biotechnology, Science Publishers.","DOI":"10.1201\/b21298"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.cbpa.2017.03.017","article-title":"Combinatorial chemistry in drug discovery","volume":"38","author":"Liu","year":"2017","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1073\/pnas.81.13.3998","article-title":"Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid","volume":"81","author":"Geysen","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1073\/pnas.82.15.5131","article-title":"General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids","volume":"82","author":"Houghten","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_65","first-page":"335","article-title":"Combinatorial chemistry: A novel method in drug discovery and its application","volume":"44","author":"Pandeya","year":"2005","journal-title":"Indian J. Chem. Sect. B Org. Med. Chem."},{"key":"ref_66","first-page":"26","article-title":"Will combinatorial chemistry keep its promise?","volume":"2","author":"Carroll","year":"2005","journal-title":"Biotechnol. Healthc."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1021\/cc700187t","article-title":"Application of combinatorial chemistry science on modern drug discovery","volume":"10","author":"Kennedy","year":"2008","journal-title":"J. Comb. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1016\/S0040-4020(01)92270-7","article-title":"COMPASS Program\u2014An original semi-empirical approach to computer-assisted synthesis","volume":"48","author":"Gordeeva","year":"1992","journal-title":"Tetrahedron"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Ho, C. (2011). Access to Medicine in the Global Economy, Oxford University Press.","DOI":"10.1093\/acprof:oso\/9780195390124.001.0001"},{"key":"ref_70","unstructured":"Gwynne, P., and Heebner, G. (2019, March 11). LABORATORY TECHNOLOGY TRENDS: Drug Discovery: 3. Available online: https:\/\/www.sciencemag.org\/site\/products\/dd3text.xhtml."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.2174\/138161207782110408","article-title":"The targets of currently used antibacterial agents: Lessons for drug discovery","volume":"13","author":"Lange","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/nbt1206-1497","article-title":"Antibacterial discovery and development-the failure of success?","volume":"24","author":"Fernandes","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"ref_73","first-page":"22","article-title":"Bacterias con alta tasa de mutaci\u00f3n:los riesgos de una vida acelerada","volume":"10","author":"Baquero","year":"2006","journal-title":"Asociaci\u00f3n Colombianade Infectolog\u00eda"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1098\/rsbl.2009.0136","article-title":"Why do species vary in their rate of molecular evolution?","volume":"5","author":"Bromham","year":"2009","journal-title":"Biol. Lett."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.tig.2011.01.005","article-title":"Horizontal gene transfer between bacteria and animals","volume":"27","year":"2011","journal-title":"Trends Genet."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1126\/science.1124410","article-title":"The Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis","volume":"312","author":"Gagneux","year":"2006","journal-title":"Science"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1128\/AAC.45.7.1994-2000.2001","article-title":"Interaction between DNA gyrase and quinolones: Effects of alanine mutations at GyrA subunit residues Ser83 and Asp87","volume":"45","author":"Barnard","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1128\/AAC.46.6.1805-1815.2002","article-title":"Quinolone-binding pocket of DNA gyrase: Role of GyrB","volume":"46","author":"Heddle","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/QCO.0b013e32830f453a","article-title":"Antimicrobial resistance in typhoidal and nontyphoidal salmonellae","volume":"21","author":"Parry","year":"2008","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/jac\/dkg222","article-title":"Mechanisms of resistance to quinolones: Target alterations, decreased accumulation and DNA gyrase protection","volume":"51","author":"Ruiz","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/emmm.200900032","article-title":"Jamming bacterial communication: New approaches for the treatment of infectious diseases","volume":"1","author":"Njoroge","year":"2009","journal-title":"EMBO Mol. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/gb-2011-12-10-229","article-title":"Revealing the molecular signatures of host-pathogen interactions","volume":"12","author":"Khor","year":"2011","journal-title":"Genome Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1046\/j.1462-5822.2001.00105.x","article-title":"EspA filament-mediated protein translocation into red blood cells","volume":"3","author":"Shaw","year":"2001","journal-title":"Cell. Microbiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1046\/j.1462-5822.2001.00146.x","article-title":"Characterization of translocation pores inserted into plasma membranes by type III-secreted Esp proteins of enteropathogenic Escherichia coli","volume":"3","author":"Ide","year":"2001","journal-title":"Cell. Microbiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.3390\/toxins2082177","article-title":"Staphylococcal enterotoxins","volume":"2","author":"Pinchuk","year":"2010","journal-title":"Toxins"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3389\/fmicb.2011.00143","article-title":"Interactions of bacterial proteins with host eukaryotic ubiquitin pathways","volume":"2","author":"Perrett","year":"2011","journal-title":"Front. Microbiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1146\/annurev-cellbio-100814-125227","article-title":"How bacteria subvert animal cell structure and function","volume":"32","author":"Jimenez","year":"2016","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"20160208","DOI":"10.1098\/rstb.2016.0208","article-title":"Membrane pores: From structure and assembly, to medicine and technology","volume":"372","author":"Gilbert","year":"2017","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1146\/annurev.cellbio.21.012704.131001","article-title":"Quorum sensing: Cell-to-Cell Communication in Bacteria","volume":"21","author":"Waters","year":"2005","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1128\/JB.185.7.2061-2065.2003","article-title":"DNA microarrays in analysis of quorum sensing: Strengths and limitations","volume":"185","author":"Vasil","year":"2003","journal-title":"J. Bacteriol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/0974-2727.78553","article-title":"Quorum sensing and Bacterial Pathogenicity: From Molecules to Disease","volume":"3","author":"Deep","year":"2011","journal-title":"J. Lab. Physicians"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1073\/pnas.91.1.197","article-title":"Structure of the autoinducer required for expression of Pseudomonas aeruginosa virulence genes","volume":"91","author":"Pearson","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1574-6976.2001.tb00583.x","article-title":"Quorum sensing in Gram-negative bacteria","volume":"25","author":"Whitehead","year":"2001","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nrmicro.2016.89","article-title":"Quorum sensing signal-response systems in gram-negative bacteria","volume":"14","author":"Papenfort","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ismej.2008.13","article-title":"AHL-driven quorum sensing circuits: Their frequency and function among the Proteobacteria","volume":"2","author":"Case","year":"2008","journal-title":"ISME J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1462-2920.2009.02049.x","article-title":"Identification and characterization of new LuxR\/LuxI-type quorum sensing systems from metagenomic libraries","volume":"12","author":"Hao","year":"2010","journal-title":"Environ. Microbiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3184\/003685006783238335","article-title":"Variations on a theme: Diverse N-acyl homoserine lactone-mediated quorum sensing mechanisms in gram-negative bacteria","volume":"89","author":"Smith","year":"2006","journal-title":"Sci. Prog."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"12619","DOI":"10.1073\/pnas.91.26.12619","article-title":"Synergistic binding of the Vibrio fischeri LuxR transcriptional activator domain and RNA polymerase to the lux promoter region","volume":"91","author":"Stevens","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nature00833","article-title":"Structure of a bacterial quorum sensing transcription factor complexed with pheromone and DNA","volume":"417","author":"Zhang","year":"2002","journal-title":"Nature"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a012427","article-title":"Bacterial quorum sensing: Its role in virulence and possibilities for its control","volume":"2","author":"Rutherford","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1128\/MMBR.00046-12","article-title":"Exploiting Quorum Sensing To Confuse Bacterial Pathogens","volume":"77","author":"LaSarre","year":"2013","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev-genet-102108-134304","article-title":"Bacterial quorum sensing network architectures","volume":"43","author":"Ng","year":"2009","journal-title":"Annu. Rev. Genet."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.chembiol.2016.01.004","article-title":"Regulation of Virulence in Staphylococcus aureus: Molecular Mechanisms and Remaining Puzzles","volume":"23","author":"Wang","year":"2016","journal-title":"Cell Chem. Biol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1128\/jb.184.4.1180-1186.2002","article-title":"High genetic variability of the agr locus in Staphylococcus species","volume":"184","author":"Dufour","year":"2002","journal-title":"J. Bacteriol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1126\/science.276.5321.2027","article-title":"Bacterial interference caused by autoinducing peptide variants","volume":"276","author":"Ji","year":"1997","journal-title":"Science"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0014-5793(98)00145-8","article-title":"Structure of the pheromone peptide of the Staphylococcus epidermidis agr system","volume":"424","author":"Otto","year":"1998","journal-title":"FEBS Lett."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"6517","DOI":"10.1128\/JB.182.22.6517-6522.2000","article-title":"Exfoliatin-producing strains define a fourth agr specificity group in Staphylococcus aureus","volume":"182","author":"Jarraud","year":"2000","journal-title":"J. Bacteriol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1046\/j.1365-2958.1996.501417.x","article-title":"Regulation of competence for genetic transformation in Streptococcus pneumoniae by an auto-induced peptide pheromone and a two-component regulatory system","volume":"21","author":"Pestova","year":"1996","journal-title":"Mol. Microbiol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev.genet.42.110807.091640","article-title":"Quorum sensing in staphylococci","volume":"42","author":"Novick","year":"2008","journal-title":"Annu. Rev. Genet."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1074\/jbc.M109989200","article-title":"Reversible and specific extracellular antagonism of receptor-histidine kinase signaling","volume":"277","author":"Lyon","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"6921","DOI":"10.1128\/JB.182.24.6921-6926.2000","article-title":"Metabolism of Acyl-Homoserine Lactone Quorum Sensing Signals by Variovorax paradoxus","volume":"182","author":"Leadbetter","year":"2000","journal-title":"J. Bacteriol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1073\/pnas.97.7.3526","article-title":"AiiA, an enzyme that inactivates the acylhomoserine lactone quorum sensing signal and attenuates the virulence of Erwinia carotovora","volume":"97","author":"Dong","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/35081101","article-title":"Quenching quorum sensing-dependent bacterial infection by an N-acyl homoserine lactonase","volume":"411","author":"Dong","year":"2001","journal-title":"Nature"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1099\/mic.0.27961-0","article-title":"N-Acylhomoserine lactone quorum-sensing molecules are modified and degraded by Rhodococcus erythropolis W2 by both amidolytic and novel oxidoreductase activities","volume":"151","author":"Uroz","year":"2005","journal-title":"Microbiology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1073\/pnas.022056699","article-title":"Genetic control of quorum sensing signal turnover in Agrobacterium tumefaciens","volume":"99","author":"Zhang","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1046\/j.1365-2958.2001.02539.x","article-title":"Structure, activity and evolution of the group I thiolactone peptide quorum sensing system of Staphylococcus aureus","volume":"41","author":"MDowell","year":"2001","journal-title":"Mol. Microbiol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"13330","DOI":"10.1073\/pnas.97.24.13330","article-title":"Rational design of a global inhibitor of the virulence response in Staphylococcus aureus, based in part on localization of the site of inhibition to the receptor-histidine kinase, AgrC","volume":"97","author":"Lyon","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.chembiol.2007.08.013","article-title":"Infection control by antibody disruption of bacterial quorum sensing signaling","volume":"14","author":"Park","year":"2007","journal-title":"Chem. Biol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1128\/IAI.67.8.3703-3713.1999","article-title":"Host-pathogen interactions: Redefining the basic concepts of virulence and pathogenicity","volume":"67","author":"Casadevall","year":"1999","journal-title":"Infect. Immun."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Green, E.R., and Mecsas, J. (2016). Bacterial secretion systems\u2014An overview. Microbiol. Spectr., 4.","DOI":"10.1128\/microbiolspec.VMBF-0012-2015"},{"key":"ref_121","first-page":"481","article-title":"The basis of virulence in Pasteurella pestis: An antigen determining virulence","volume":"37","author":"Bacon","year":"1956","journal-title":"Br. J. Exp. Pathol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1126\/science.2166336","article-title":"Protein tyrosine phosphatase activity of an essential virulence determinant in Yersinia","volume":"249","author":"Guan","year":"1990","journal-title":"Science"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1365-2958.1996.tb02546.x","article-title":"YopH of Yersinia pseudotuberculosis interrupts early phosphotyrosine signalling associated with phagocytosis","volume":"20","author":"Andersson","year":"1996","journal-title":"Mol. Microbiol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1128\/iai.56.8.2139-2143.1988","article-title":"Inhibition of phagocytosis in Yersinia pseudotuberculosis: A virulence plasmid-encoded ability involving the Yop2b protein","volume":"56","author":"Rosqvist","year":"1988","journal-title":"Infect. Immun."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/j.1460-2075.1992.tb05253.x","article-title":"IpaB of Shigella flexneri causes entry into epithelial cells and escape from the phagocytic vacuole","volume":"11","author":"High","year":"1992","journal-title":"EMBO J."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1128\/jb.175.18.5899-5906.1993","article-title":"Nonpolar mutagenesis of the ipa genes defines IpaB, IpaC, and IpaD as effectors of Shigella flexneri entry into epithelial cells","volume":"175","author":"Menard","year":"1993","journal-title":"J. Bacteriol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1093\/emboj\/16.10.2717","article-title":"Modulation of bacterial entry into epithelial cells by association between vinculin and the Shigella IpaA invasin","volume":"16","author":"Sansonetti","year":"1997","journal-title":"EMBO J."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1126\/science.7716514","article-title":"Integrins and signal transduction pathways: The road taken","volume":"268","author":"Clark","year":"1995","journal-title":"Science"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1084\/jem.183.3.991","article-title":"Interaction of Ipa proteins of Shigella flexneri with alpha5beta1 integrin promotes entry of the bacteria into mammalian cells","volume":"183","author":"Watarai","year":"1996","journal-title":"J. Exp. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1046\/j.1462-5822.2001.00159.x","article-title":"Role of EscF, a putative needle complex protein, in the type III protein translocation system of enteropathogenic Escherichia coli","volume":"3","author":"Wilson","year":"2001","journal-title":"Cell. Microbiol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/7391","article-title":"Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury","volume":"5","author":"Sawa","year":"1999","journal-title":"Nat. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1086\/430932","article-title":"Protective anti-V antibodies inhibit Pseudomonas and Yersinia translocon assembly within host membranes","volume":"192","author":"Goure","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1128\/IAI.00815-08","article-title":"An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity","volume":"77","author":"Baer","year":"2009","journal-title":"Infect. Immun."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1046\/j.1365-2958.2001.02411.x","article-title":"MicroReview Sortase-catalysed anchoring of surface proteins to the cell wall of Staphylococcus aureus","volume":"40","author":"Mazmanian","year":"2001","journal-title":"Mol. Microbiol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tim.2004.03.004","article-title":"Assembly of pili in gram-positive bacteria","volume":"12","author":"Schneewind","year":"2004","journal-title":"Trends Microbiol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0092-8674(92)90101-H","article-title":"Sorting of protein A to the staphylococcal cell wall","volume":"70","author":"Schneewind","year":"1992","journal-title":"Cell"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1046\/j.1365-2958.2003.03782.x","article-title":"Assembly of pili on the surface of Corynebacterium diphtheriae","volume":"50","author":"Schneewind","year":"2003","journal-title":"Mol. Microbiol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/nbt0905-1073","article-title":"Monoclonal antibody successes in the clinic","volume":"23","author":"Reichert","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2471\/BLT.16.178061","article-title":"Therapeutic antibodies for infectious diseases","volume":"95","author":"Sparrow","year":"2017","journal-title":"Bull. World Health Organ."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1128\/AAC.00343-09","article-title":"Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli","volume":"54","author":"Contrini","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1128\/AAC.01661-08","article-title":"Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteers","volume":"53","author":"Bitzan","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40265-016-0577-0","article-title":"Obiltoxaximab: First Global Approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"531","DOI":"10.4161\/mabs.1.6.10195","article-title":"Raxibacumab","volume":"1","author":"Mazumdar","year":"2009","journal-title":"MAbs"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrmicro2421","article-title":"Interactions between bacterial pathogens and mitochondrial cell death pathways","volume":"8","author":"Rudel","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1146\/annurev-immunol-031210-101405","article-title":"The inflammasome NLRs in immunity, inflammation, and associated diseases","volume":"29","author":"Davis","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrmicro2070","article-title":"Pyroptosis: Host cell death and inflammation","volume":"7","author":"Bergsbaken","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.cell.2010.02.015","article-title":"Decoding cell death signals in inflammation and immunity","volume":"140","author":"Zitvogel","year":"2010","journal-title":"Cell"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1083\/jcb.201108081","article-title":"Cell death and infection: A double-edged sword for host and pathogen survival","volume":"195","author":"Ashida","year":"2011","journal-title":"J. Cell Biol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1164\/ajrccm.160.supplement_1.4","article-title":"Granulocyte apoptosis and its role in the resolution and control of lung inflammation","volume":"160","author":"Haslett","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.chom.2010.06.007","article-title":"Manipulation of host cell death pathways during microbial infections","volume":"8","author":"Lamkanfi","year":"2010","journal-title":"Cell Host Microbe"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cell.2012.06.019","article-title":"The RIP1\/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis","volume":"150","author":"Li","year":"2012","journal-title":"Cell"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nature14191","article-title":"Necroptosis and its role in inflammation","volume":"517","author":"Pasparakis","year":"2015","journal-title":"Nature"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"9505","DOI":"10.1074\/jbc.M109488200","article-title":"Identification of a novel homotypic interaction motif required for the phosphorylation of receptor-interacting protein (RIP) by RIP3","volume":"277","author":"Sun","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.4049\/jimmunol.174.8.4942","article-title":"Apoptosis induced by the toll-like receptor adaptor TRIF is dependent on its receptor interacting protein homotypic interaction motif","volume":"174","author":"Kaiser","year":"2005","journal-title":"J. Immunol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/embor.2009.109","article-title":"DAI\/ZBP1 recruits RIP1 and RIP3 through RIP homotypic interaction motifs to activate NF-kappaB","volume":"10","author":"Rebsamen","year":"2009","journal-title":"EMBO Rep."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"16258","DOI":"10.1038\/nmicrobiol.2016.258","article-title":"EspL is a bacterial cysteine protease effector that cleaves RHIM proteins to block necroptosis and inflammation","volume":"2","author":"Pearson","year":"2017","journal-title":"Nat. Microbiol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/415389a","article-title":"Antimicrobial peptides of multicellular organisms","volume":"415","author":"Zasloff","year":"2002","journal-title":"Nature"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nri1180","article-title":"Defensins: Antimicrobial peptides of innate immunity","volume":"3","author":"Ganz","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"R14","DOI":"10.1016\/j.cub.2015.11.017","article-title":"Antimicrobial peptides","volume":"26","author":"Zhang","year":"2016","journal-title":"Curr. Biol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ijantimicag.2004.09.005","article-title":"Antimicrobial peptides: Premises and promises","volume":"24","author":"Reddy","year":"2004","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"6257","DOI":"10.4049\/jimmunol.174.10.6257","article-title":"Mouse cathelin-related antimicrobial peptide chemoattracts leukocytes using formyl peptide receptor-like 1\/mouse formyl peptide receptor-like 2 as the receptor and acts as an immune adjuvant","volume":"174","author":"Kurosaka","year":"2005","journal-title":"J. Immunol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1084\/jem.192.7.1069","article-title":"LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells","volume":"192","author":"Yang","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/intimm\/14.4.421","article-title":"Epithelial cell-derived human beta-defensin-2 acts as a chemotaxin for mast cells through a pertussis toxin-sensitive and phospholipase C-dependent pathway","volume":"14","author":"Niyonsaba","year":"2002","journal-title":"Int. Immunol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1471-4906(02)02246-9","article-title":"Mammalian defensins in immunity: More than just microbicidal","volume":"23","author":"Yang","year":"2002","journal-title":"Trends Immunol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1172\/JCI114394","article-title":"Monocyte-chemotactic activity of defensins from human neutrophils","volume":"84","author":"Territo","year":"1989","journal-title":"J. Clin. Investig."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1523-1747.2003.12069.x","article-title":"The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium","volume":"120","author":"Heilborn","year":"2003","journal-title":"J. Investig. Dermatol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.peptides.2008.11.001","article-title":"Antimicrobial human beta-defensin-2 stimulates migration, proliferation and tube formation of human umbilical vein endothelial cells","volume":"30","author":"Baroni","year":"2009","journal-title":"Peptides"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.4049\/jimmunol.175.7.4662","article-title":"Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37","volume":"175","author":"Tokumaru","year":"2005","journal-title":"J. Immunol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.it.2008.12.003","article-title":"AMPed Up immunity: How antimicrobial peptides have multiple roles in immune defense","volume":"30","author":"Gallo","year":"2009","journal-title":"Trends Immunol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.4049\/jimmunol.169.7.3883","article-title":"The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses","volume":"169","author":"Scott","year":"2002","journal-title":"J. Immunol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.4049\/jimmunol.171.12.6690","article-title":"The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor","volume":"171","author":"Tjabringa","year":"2003","journal-title":"J. Immunol."},{"key":"ref_172","first-page":"3760","article-title":"The role of the multifunctional peptide LL-37 in host defense","volume":"13","author":"Agerberth","year":"2008","journal-title":"Front. Biosci."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1074\/jbc.273.6.3718","article-title":"Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37","volume":"273","author":"Johansson","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000092305","article-title":"Human cathelicidin LL-37 is a chemoattractant for eosinophils and neutrophils that acts via formyl-peptide receptors","volume":"140","author":"Tjabringa","year":"2006","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.4049\/jimmunol.176.5.3044","article-title":"An antimicrobial cathelicidin peptide, human CAP18\/LL-37, suppresses neutrophil apoptosis via the activation of formyl-peptide receptor-like 1 and P2X7","volume":"176","author":"Nagaoka","year":"2006","journal-title":"J. Immunol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1189\/jlb.1005560","article-title":"The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system","volume":"80","author":"Barlow","year":"2006","journal-title":"J. Leukoc. Biol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00011-005-0062-9","article-title":"Mechanisms of cell death induced by the neutrophil antimicrobial peptides alpha-defensins and LL-37","volume":"55","author":"Aarbiou","year":"2006","journal-title":"Inflamm. Res."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Ciornei, C.D., Tapper, H., Bjartell, A., Sternby, N.H., and Bodelsson, M. (2006). Human antimicrobial peptide LL-37 is present in atherosclerotic plaques and induces death of vascular smooth muscle cells: A laboratory study. BMC Cardiovasc. Disord., 6.","DOI":"10.1186\/1471-2261-6-49"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrmicro2745","article-title":"Modulating immunity as a therapy for bacterial infections","volume":"10","author":"Hancock","year":"2012","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1574-6968.1998.tb12896.x","article-title":"Mechanism of antimicrobial action of indolicidin","volume":"160","author":"Subbalakshmi","year":"1998","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1432-1033.1993.tb18182.x","article-title":"Isolation of three antibacterial peptides from pig intestine: Gastric inhibitory polypeptide(7\u201342), diazepam-binding inhibitor(32\u201386) and a novel factor, peptide 3910","volume":"216","author":"Agerberth","year":"1993","journal-title":"Eur. J. Biochem."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"e02340-16","DOI":"10.1128\/AAC.02340-16","article-title":"Intracellular targeting mechanisms by antimicrobial peptides","volume":"61","author":"Le","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"8245","DOI":"10.1073\/pnas.150518097","article-title":"Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: The proline hinge is responsible for the cell-penetrating ability of buforin II","volume":"97","author":"Park","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1128\/AAC.41.8.1738","article-title":"Protegrin-1: A broad-spectrum, rapidly microbicidal peptide with in vivo activity","volume":"41","author":"Steinberg","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.3390\/ph6081055","article-title":"Characterization of antimicrobial peptides toward the development of novel antibiotics","volume":"6","author":"Aoki","year":"2013","journal-title":"Pharmaceuticals"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"7553","DOI":"10.1021\/ja0107475","article-title":"De Novo Design, Synthesis, and Characterization of Antimicrobial \u03b2-Peptides","volume":"123","author":"Liu","year":"2001","journal-title":"J. Am. Chem. Soc."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/nature05233","article-title":"A linguistic model for the rational design of antimicrobial peptides","volume":"443","author":"Loose","year":"2006","journal-title":"Nature"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/6\/1255\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:38:21Z","timestamp":1760186301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/6\/1255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,13]]},"references-count":187,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["ijms20061255"],"URL":"https:\/\/doi.org\/10.3390\/ijms20061255","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,13]]}}}